Exoskeleton pricing is becoming easier to see and harder to describe with one number. In 2026, a powered consumer system can be bought for less than US$700. A targeted passive neck support can be listed at €195 excluding VAT (≈US$219), while an active grip-assistance system is listed at €9,995 (≈US$11,247). They are not substitutes. A personal medical system can carry a documented acquisition cost of €49,900 (≈US$56,152), while another commercially available medical exoskeleton may publish no conventional retail price at all.

Those figures are not contradictory. They belong to different markets and, just as importantly, to different kinds of transactions.

A checkout price, a promotion, a multi-user deployment, a lease, a hospital award, a financing programme and a reimbursement benchmark can all be legitimate pricing evidence. The mistake is treating them as interchangeable versions of “the price of an exoskeleton.” Once that happens, a range that looks precise can become analytically meaningless.

This Price Intelligence analysis therefore asks a narrower set of questions: what is being priced, who is actually paying, through which route, and what does the number represent? That approach reveals something more interesting than a simple price list. It shows where the exoskeleton market is becoming genuinely retail, where deployment economics are taking over, and where price transparency still depends on institutional or clinical access.

Retail

What can an individual actually buy today?

Deployment

How do fleet, subscription and leasing models change the economics?

Institutional

What do hospitals and public buyers actually pay?

Access

When does a price become part of financing, prescription or reimbursement?

Price transparency is becoming a market signal

The exoskeleton market is no longer uniformly opaque. Consumer products increasingly behave like premium electronics: buyers can see a product page, compare variants, watch promotions move and reach checkout without speaking to a sales team. Workplace suppliers increasingly publish unit prices while also offering pilots, enterprise packages, subscriptions or leasing. Medical exoskeletons remain more likely to move through assessment, quotation, procurement or reimbursement.

That difference matters because price transparency offers one indicator of how a market is commercializing. Multiple current public offers make comparison shopping and visible price competition possible. Quote-led markets can be commercially mature too; their price signals are simply harder to isolate from configuration, service, clinical requirements and the buyer’s institution. Transparency is therefore evidence of a sales model, not a quality or maturity score by itself.

Editorial illustration showing consumer outdoor mobility, workplace lifting assistance and medical rehabilitation as three distinct exoskeleton markets.
One technology, three markets. The illustration distinguishes consumer, workplace and medical contexts; it does not depict specific commercially verified products.

The same device family can also produce several valid numbers at once. An employer may see an individual purchase price, a per-user enterprise package and a monthly service model. A hospital may see an acquisition cost and a separate reimbursement framework. None of those numbers should automatically overwrite the others.

The consumer market now has a floor, a competitive core and a premium edge

The clearest pricing shift in 2026 is happening in consumer mobility. There are now enough directly purchasable powered systems for the category to develop a visible price structure rather than a handful of isolated launch prices.

At the entry point, DNSYS advertises X1 Lite at US$689. That pushes the direct-buy floor for a powered hip-assist system below US$700. The larger commercial signal, however, is not one low price. It is the concentration of competing products around roughly US$900–US$2,000, where Hypershell, VIGX, NAVEE, Ascentiz and DNSYS now expose offers that buyers can compare in public.

System Current public price Context Access
DNSYS X1 Lite US$689 Entry X1 configuration Direct purchase
DNSYS X1 Carbon US$829–889 Current first-party surfaces disagree; both show a US$1,299 reference price Direct purchase
Hypershell X Pro S US$999Europe: €999 ≈ US$1,124 Regional storefront pricing Direct purchase
VIGX π US$1,099 Reference price US$1,199 Direct purchase
NAVEE EXO S Pro €1,099≈ US$1,237 European direct price Direct purchase
Ascentiz H Pro US$1,299 standardUS$1,199 limited promotion observed 17 Oct Short-lived promotion kept separate from standard price Direct purchase
VIGX π Plus US$1,399 Reference price US$1,499 Direct purchase
Hypershell X Max S US$1,499Europe: €1,499 ≈ US$1,687 Regional storefront pricing Direct purchase
Ascentiz H Ultra US$1,699 standardUS$1,599 limited promotion observed 17 Oct Standard price retained as the durable comparison point Direct purchase
Hypershell X Ultra S US$1,999Europe: €1,999 ≈ US$2,249 Regional storefront pricing Direct purchase
VIGX Ant-H1 Pro US$1,999.99 Official direct-store offer; model and use case differ from the VIGX π range Direct purchase
THE CONSUMER PRICE LANDSCAPEA consumer market is beginning to formThe important signal is not one cheapest product. It is the emergence of three recognizable commercial zones.
ENTRYBelow US$700

DNSYS X1 Lite brings a powered hip-assist system into sub-US$700 territory.

CORE RETAIL~US$900–US$2,000

The densest current competition, where multiple brands expose comparable public offers.

PREMIUM / DIFFERENT ARCHITECTURE~US$2,300–US$5,000

Full-leg, ankle-assist and premium mobility systems move beyond the core band for different reasons.

The upper end has not disappeared as the entry floor moved down. Hypershell Halo is US$2,299, Dephy Sidekick is US$4,500 and the Skip × Arc’teryx MO/GO Starter Pack is US$4,999. Those products should not be read as simply “expensive versions” of the US$1,000 class. Hip-and-knee assistance, powered ankle assistance and a premium reservation model are different propositions.

When transparency creates a new problem: conflicting first-party prices

DNSYS X1 Carbon currently appears at both US$829 and US$889 across official DNSYS surfaces, each against a US$1,299 reference price. The US$829 figure appears on a current official localized surface; US$889 appears on another official surface. These are manufacturer-displayed USD amounts, but they are not a verified universal checkout range for every destination. We report both rather than inventing a midpoint, and buyers should confirm the selected variant and delivery region at checkout.

Ascentiz illustrates a related but different issue. A temporary campaign can be a valid current offer without becoming the durable comparison price. For that reason, the main table retains the standard prices displayed on the H Pro and H Ultra product pages. Their US$1,199 / US$1,599 Fall Hiking Sale offers were observed on 17 October and were advertised to end on 18 October 2026 (PDT). They are historical, dated offer evidence after that cutoff, not permanent market prices.

The consumer story is no longer simply that powered exoskeletons are getting cheaper. It is that enough products now occupy the same public price territory for normal retail competition to become visible.

The workplace market is splitting by architecture, not just by price

“Industrial exoskeletons cost hundreds to several thousand euros” is still technically defensible and increasingly unhelpful. A passive neck support, a textile lifting suit, an overhead system, a powered lumbar exoskeleton and an active grip device solve different ergonomic problems. Their prices diverge because their architectures and service requirements diverge.

What changed in 2026 is that the powered side of the workplace market is becoming easier to observe. Public pricing is still far from universal, but it is no longer limited to passive or mechanically assisted products.

System Architecture Current public price Commercial meaning
Skelex Neck Passive · neck €195 ex VAT≈ US$219 Targeted support
HUNIC SoftExo Carry Passive · carrying €490 net≈ US$551 Direct unit price
Skelex Edge Passive · back / lifting €915 ex VAT≈ US$1,030 Purchase option
Auxivo LiftSuit 2 Passive · back / lifting CHF 950≈ US$1,153 Manufacturer list price
HeroWear Apex 2 Passive · back assist US$1,999 individual Enterprise and service routes also available
VIGX Q20 Powered · lumbar US$2,399 Direct public offer
VIGX A10 Powered · arm assist US$2,999 Direct public offer
VIGX Y20 Powered · lumbar US$4,599 Direct public offer
exoIQ B900 Powered · active back €6,900 ex VAT≈ US$7,765 Purchase + leasing example
Skelex Ironhand Powered · grip €9,995≈ US$11,247 Specialist active system

The table shows why the broad industrial range is becoming less meaningful. The low and high ends are not substitutes. They represent different body areas, engineering complexity and deployment burdens. The better question is not “what is the average industrial exoskeleton price?” but what does it cost to address this task with this type of assistance?

The commercial model can matter almost as much as the hardware

HeroWear lists an individual Apex 2 at US$1,999. Its published workplace packages for 10, 25 and 50 users work out to US$1,499 per user, while qualifying Exoskeleton as a Service deployments start below US$99 per user per month. Skelex likewise publishes purchase and recurring plans. exoIQ lists a €6,900 ex-VAT purchase price for B900 (≈US$7,765) alongside a leasing example of €154.97 per month (≈US$174) over 48 months.

Those numbers should not be collapsed into one “price.” They show a market learning to sell deployment, not just hardware.

Medical exoskeletons have commercial prices without behaving like retail products

Medical pricing is where ordinary product-price logic breaks most quickly. A commercial medical exoskeleton may require assessment, prescription, fitting, patient training, payer approval or institutional purchasing before a transaction occurs. That means commercial availability can be real even when there is no public checkout price.

System Published pricing evidence What the number means Access route
Marsi Bionics EXPLORER MB €49,900≈ US$56,152 Documented acquisition cost in the current Spanish financing pathway Assessment + financing / purchase
ANGEL LEGS M20 ₩120,000,000 domestic≈ US$90,083US$85,000 export Manufacturer standard sales prices; VAT separate Institutional / specialist sale
ANGEL SUIT H10 ₩31,500,000≈ US$23,647 Manufacturer standard sales price; VAT separate Institutional / specialist sale
Wandercraft Eve Price not publicly disclosed Commercial US launch without ordinary retail pricing Evaluation + physician order + fitting
Trexo Theo Price confirmed after assessment Configuration and price confirmed before purchase agreement Assessment + prescription
ReWalk 7 Coverage pathway Do not substitute Medicare reimbursement for retail price Prescription + payer / specialist pathway

Why the €49,900 (≈US$56,152) EXPLORER MB figure matters

The EXPLORER MB figure is unusually useful because the current Spanish access programme names the product and states an acquisition cost of €49,900 (≈US$56,152). It is stronger evidence than an anonymous tender ceiling or an old distributor listing. It is still not a universal global MSRP. The correct wording is that €49,900 (≈US$56,152) is a documented acquisition cost in the current Spanish financing pathway.

Commercial availability does not require a public sticker price

Wandercraft Eve makes the opposite point. Eve entered commercial launch in the United States in September 2026, but access involves evaluation, physician order, individualized fitting and training rather than a standard ecommerce transaction. “Available for purchase” and “priced like a consumer product” are not the same thing.

Procurement data is powerful precisely because it is specific

Public procurement gives the market something manufacturer marketing often does not: a recorded transaction between a named buyer and supplier. It is some of the strongest price evidence available for institutional exoskeletons. It is also easy to misuse.

Buyer / country System Transaction value Approx. equivalent
National Rehabilitation Assistive Products Research Center affiliated hospital · China ZEPU-AI9 · 1 unit CNY 545,000 ≈ US$81,511
Ningxia Medical University General Hospital · China ZEPU-AI9 · 1 unit CNY 599,800 ≈ US$89,707
Guangdong Provincial Hospital of TCM Hainan Hospital · China Fourier M4L02L · 2 units CNY 1,175,000 per unit ≈ US$175,735
Hangzhou Rehabilitation Hospital · China UGO223 · 1 unit CNY 580,000 ≈ US$86,746
Wangcang County Hospital of TCM · China Aider3S-310 · 1 unit CNY 470,000 ≈ US$70,294
Hospital Nacional de Parapléjicos, Toledo · Spain Adult gait exoskeleton · model not named €90,000≈ US$101,277 GOGOA Mobility Robots awarded supplier
Hospital Universitario Dr José Molina Orosa, Lanzarote · Spain Lower-limb robotic exoskeleton · model not named €95,000≈ US$106,904 ABLE Human Motion awarded supplier

The same ZEPU-AI9 appears at institutional prices about 10% apart

One Chinese public buyer paid CNY 545,000 (≈US$81,511) for a ZEPU-AI9. Another paid CNY 599,800 (≈US$89,707). The second transaction is roughly 10.1% higher for the same named system. That is direct evidence that procurement price is transaction-specific. Timing, distributor structure, training, service, contract scope and competitive conditions can all change the award.

The Spanish cases demonstrate another form of discipline. The procurement records identify the awarded suppliers but do not provide enough evidence to map each transaction confidently to one exact named product. Exoskeleton Index therefore keeps the contract value without inventing model-level precision.

Reimbursement is another price layer, not a retail substitute

Lifeward’s September 2026 investor material cites a US$95,081 Medicare Fee Schedule payment amount for HCPCS K1007. That benchmark matters for qualifying personal exoskeleton claims. It does not establish a universal manufacturer retail price for ReWalk 7.

South Korea makes the distinction even clearer: the reimbursed object can be a robot-assisted gait-training session rather than the robot itself. In that case the payer is funding treatment, not transferring ownership of the device.

Editorial illustration of four distinct commercial contexts for exoskeleton pricing: retail, workplace deployment, institutional procurement and reimbursement.
Four prices, four different questions. These are distinct commercial or funding categories, not successive steps in one required purchasing pathway.

Procurement and reimbursement become misleading only when they are promoted into something they are not: a universal product price.

What price can tell us about market maturity

The deeper signal in the 2026 dataset is not simply where prices are high or low. It is where prices are becoming comparable.

PRICE INTELLIGENCE LENS

Transparency is developing at different speeds

01Consumer

Competition is visible

Multiple public offers now sit in overlapping price bands. Promotions, regional storefronts and even first-party conflicts are visible because the market has become transparent enough for them to be observed.

02Workplace

Deployment is becoming the product

Public unit prices increasingly coexist with fleet packages, subscriptions and leasing. Price intelligence therefore has to track the commercial route, not only the hardware.

03Medical

Access still shapes the price

Transparent manufacturer prices remain less common. Assessment, prescription, financing, procurement and reimbursement still define how many transactions actually happen.

This makes price transparency more than a convenience for buyers. It is evidence of how a category is commercializing. A market with multiple public offers can support ordinary competitive pressure. A market dominated by quotations and institutional transactions remains more dependent on service, configuration and access infrastructure.

The sticker price is only the beginning of ownership cost

A lower purchase price does not automatically create better value. Consumer buyers still need to normalize battery count, charger, replacement batteries, compatible footwear or accessories, shipping, taxes, warranty, returns and software. A US$1,699 system and a US$1,999 system can move much closer together once the package is normalized.

South Korea’s WIRobotics WIM S provides a concrete consumer ownership example outside the main hip-assist table. Its domestic direct-purchase price is ₩2,790,000 (≈US$2,094). Optional WIM Premium software for one device is ₩9,900/month (≈US$7.43) or ₩79,000/year (≈US$59.30). These Korean prices illustrate a small but real recurring service layer on top of hardware ownership; they are not international selling prices.

For workplaces, deployment cost can include fitting, user selection, training, hygiene, storage, replacement textiles, batteries, maintenance, pilot measurement, downtime and supplier support. Utilization is part of the economics. A low-cost product that workers leave in a locker can create worse value than a more expensive system that fits the task and is used consistently.

For medical buyers, hardware can sit inside a broader pathway involving assessment, therapist time, patient training, maintenance, funding approval and reimbursement. The device price may be only one component of the programme.

The Exoskeleton Index view

The most important pricing development in 2026 is not one unusually cheap consumer product or one expensive medical system. It is that the market is becoming easier to separate into distinct commercial layers.

Consumer exoskeletons now have a visible entry floor, a competitive retail core and a premium edge. Workplace systems are beginning to separate by architecture while suppliers experiment with purchase, enterprise packages, subscriptions and leasing. Medical systems remain more dependent on specialist access, but disclosures such as EXPLORER MB’s €49,900 (≈US$56,152) Spanish acquisition cost make parts of that market more legible. Procurement and reimbursement add valuable evidence only when they remain in their own categories.

That is why a statement such as “exoskeletons cost from a few hundred dollars to more than US$100,000” is technically possible and analytically weak. It combines products that solve different problems with numbers that represent different transactions.

The question that matters

Not simply: “How much does an exoskeleton cost?”

But: which product class, through which commercial route, in which region, with what included, and what does that number actually represent?

Methodology

This analysis uses Exoskeleton Index’s structured commercial price-offer layer as the primary source for current product pricing, supplemented by manufacturer storefronts, official catalogues, corporate filings, public procurement records and payer documentation.

Commercial evidence is prioritised in this order:

Current manufacturer storefront or official checkout.
Current manufacturer catalogue or official pricing page.
Official corporate filing or current commercial document.
Authorised distribution evidence where manufacturer pricing is unavailable.
Legacy Exoskeleton Index pricing only as historical or fallback context.

The evidence cutoff for this analysis is 17 October 2026, with selected first-party offers rechecked on 18 October. Skelex Neck and Edge prices were rechecked on 30 October 2026. Original currencies remain canonical, but every non-USD monetary figure in the analysis is paired with an approximate USD equivalent so readers can compare scale consistently. Conversions use European Central Bank reference rates for 16 October 2026, the latest working-day reference before the evidence cutoff: €1 = US$1.1253, ¥177.82, CHF 0.9272, CNY 7.5240 and ₩1,499.01.

Promotions are treated as dated offers, not permanent prices. A deposit is not treated as the total product price. Procurement awards are not treated as MSRP. Reimbursement values are not treated as retail. Where two current first-party price surfaces disagree, the conflict remains visible rather than being averaged away.

Prices, promotions, taxes, stock and regional availability can change quickly. This article is an evidence-led market snapshot rather than a binding quote.

Frequently asked questions

How much does an exoskeleton cost in 2026?

Direct-buy consumer powered exoskeletons now start below US$700, with the strongest current retail competition around roughly US$900–US$2,000. Premium or different-architecture personal systems can move toward US$2,300–US$5,000. Workplace systems range from low-cost passive supports to powered products around €6,900 (≈US$7,765) and specialist active systems near €10,000 (≈US$11,253). Medical acquisition costs can reach tens of thousands, while many systems remain quote-based.

What is the cheapest powered consumer exoskeleton in this guide?

DNSYS currently advertises X1 Lite at US$689. That is an entry configuration, not a universal price for every X1 variant.

Why do different official pages show different prices for the same exoskeleton?

Region, promotion, variant, package and storefront configuration can all change the offer. DNSYS X1 Carbon is a current example where first-party surfaces expose different prices. Exoskeleton Index records the conflict instead of averaging it.

How much does an industrial exoskeleton cost?

There is no single useful industrial range. Passive and mechanical workplace systems can cost from hundreds to a few thousand euros or dollars, while powered public-price examples now extend materially higher. Task and architecture should be defined before price comparison.

How much does a medical exoskeleton cost?

Published figures can reach tens of thousands. Marsi Bionics EXPLORER MB has a documented €49,900 (≈US$56,152) acquisition cost in a current Spanish financing pathway, while Angel Robotics publishes standard sales prices for selected systems. Other products remain assessment- or quote-based.

Is Medicare’s K1007 amount the retail price of ReWalk 7?

No. The 2026 US$95,081 figure cited by Lifeward is a Medicare Fee Schedule payment benchmark. It should not be presented as a universal manufacturer retail price.

Why can the same medical exoskeleton appear at different hospital prices?

Public procurement can vary with contract scope, distributor, timing, training, warranty, service and competition. Two Chinese public buyers acquired the same ZEPU-AI9 at values about 10% apart.

Selected sources

  1. DNSYS: X1 product page, X1 collection.
  2. Hypershell: US storefront and EU X Series.
  3. VIGX: current consumer and workplace catalog, including Q20, A10 and Y20.
  4. Ascentiz: H Pro product page and H Ultra product page. The October 17 promotional values in the comparison are dated observations, not standing prices.
  5. NAVEE: EXO S Pro European listing.
  6. WIRobotics: WIM S official South Korean store and WIM Premium monthly and annual subscription prices.
  7. Dephy: Sidekick Starter Pack.
  8. Skip: MO/GO reservation terms.
  9. HeroWear: Apex 2 pricing and service models.
  10. Skelex: published purchase and recurring plans, plus current shop prices (Neck and Edge rechecked 30 October 2026).
  11. HUNIC: SoftExo direct pricing.
  12. Auxivo: official product pricing.
  13. Hilti: EXO-S.
  14. exoIQ: B900 purchase and leasing information.
  15. Innophys: Every-Light monitor sale and Soft-ARM commercial launch, Soft-ARM specifications and price.
  16. Innophys: Exo-Power price and product information.
  17. Angel Robotics: 2025 annual report published in 2026.
  18. Trexo Robotics: assessment, prescription and purchase pathway.
  19. Wandercraft: Eve US commercial launch.
  20. CaixaBank / MicroBank: EXPLORER MB financing and €49,900 (≈US$56,152) acquisition cost.
  21. China Government Procurement: ZEPU-AI9 · CNY 545,000 (≈US$81,511).
  22. Ningxia Government Procurement: ZEPU-AI9 · CNY 599,800 (≈US$89,707).
  23. China Government Procurement: Fourier M4L02L procurement.
  24. China Government Procurement: UGO223 procurement and Aider3S-310 procurement.
  25. Spain public procurement: Hospital Nacional de Parapléjicos, Toledo, tender 2026/034691; and Hospital Dr José Molina Orosa, Lanzarote, government tender record. Supplier/model details require their underlying award documentation.
  26. Lifeward: September 2026 investor presentation citing the 2026 K1007 Medicare Fee Schedule payment amount.
  27. European Central Bank: 16 October 2026 euro reference rates.

Editorial note: This article is independently prepared by Exoskeleton Index using current manufacturer storefronts, catalogues, corporate statements, public procurement records, payer documentation and its structured price-offer database. The two illustrations are editorial concepts, not photographs or technically verified depictions of a named exoskeleton. Manufacturer prices, promotions, taxes, stock and commercial terms can change. Approximate currency conversions are provided for comparison only.

Buyer support

Need help evaluating the options?

Tell us your use case, organisation or region and what you are trying to evaluate. Exoskeleton Index can help identify relevant products and suppliers.

Get help building a shortlist